Tyrosine Kinases

A tyrosine kinase is an enzyme that can transfer a phosphate group from ATP to a protein in a cell. It functions as an "on" or "off" switch in many cellular functions. Tyrosine kinases are a subclass of protein kinase.The phosphate group is attached to the amino acid tyrosine on the protein. Tyrosine kinases are a subgroup of the larger class of protein kinases that attach phosphate groups to other amino acids (serine and threonine). Phosphorylation of proteins by kinases is an important mechanism in communicating signals within a cell (signal transduction) and regulating cellular activity, such as cell division.

Cat. No.	Product name	CAS No.	Purity
T6933	Peficitinib	944118-01-8	98.67%
T6933	Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.
T36584	HNMPA-(AM)3	120944-03-8	97.22%
T36584	HNMPA-(AM)3 inhibits activation of ERK phosphorylation and stimulation of ecdysteroid production by prothyrotropin (PTTH). Furthermore, HNMPA-(AM)3 had inhibitor...
T14669	BMS-066	914946-88-6	98%
T14669	BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.
T17184	Tyrosine kinase inhibitor	1021950-26-4	98%
T17184	Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.
T13233	Tyk2-IN-3	1779493-12-7	98%
T13233	Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).
T5049	NVP-BSK805	1092499-93-8	98%
T5049	NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.
T6790	BMS-911543	1271022-90-2	99.98%
T6790	BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, ~350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. Phase 1/2.
T1936	Alectinib	1256580-46-7	99.97%
T1936	Alectinib (RG-7853) is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
T3061	Lorlatinib	1454846-35-5	99.93%
T3061	Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1...
T1917	GSK 3 Inhibitor IX	667463-62-9	99.9%
T1917	GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity w...
T13237L	Ropsacitinib	2127109-84-4	99.85%
T13237L	Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).
T2485	Baricitinib	1187594-09-7	99.79%
T2485	Baricitinib (INCB028050) is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineopla...
T1835	Ibrutinib	936563-96-1	99.76%
T1835	Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T71857	GTP-14564	34823-86-4	99.69%
T71857	GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba/F1 expressi...
T12266L	Ilginatinib maleate	1354799-87-3	99.68%
T12266L	Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.
T2636	Decernotinib	944842-54-0	99.64%
T2636	Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.
T2487	Cerdulatinib	1198300-79-6	99.64%
T2487	Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.
T12266L2	Ilginatinib hydrochloride	1239358-85-0	99.55%
T12266L2	Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.
T6080	NVP-AEW541	475489-16-8	99.55%
T6080	NVP-AEW541 (AEW541), a potent inhibitor of IGF-1R(IC50=150 nM) and InsR(IC50=140 nM), exhibits excellent efficiency and specificity for IGF-1R in a cell-based as...
T6156	Ruxolitinib (S enantiomer)	941685-37-6	99.5%
T6156	Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.